FDA Warns Against Using Compounded Remdesivir Due To Quality Concerns
Executive Summary
Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.
You may also be interested in...
US COVID-19 Fraud: OTC Injectable Peptides Promoted As Treatment
Paradigm RE advised to take immediate action to correct violations for suggesting its injectable peptides could reduce acute lung injury in patients with COVID-19.
US COVID-19 Fraud: FTC Points To Peptides As Latest Scam, Silver Remedy Firm Shut Down
FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.
Gilead’s Veklury Approval Shows US FDA’s Existing Regulatory Tools Are Up To The COVID-19 Challenge
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.